Opinion
Video
The Impact of Respiratory Syncytial Virus (RSV) on Vulnerable Populations
Author(s):
A panelist discusses how physicians can recognize the burden of RSV in high-risk populations, stay informed about preventive strategies such as vaccines and monoclonal antibodies, and apply clinical insights to reduce severe outcomes and hospitalizations.
Summary for Physicians: RSV Overview
RSV is a common, seasonal virus causing lower respiratory tract infections, especially bronchiolitis and pneumonia. It poses significant risks to vulnerable groups, such as infants (particularly those who are premature), older adults, and those with chronic conditions or immunosuppression. While often mild, RSV can lead to severe illness and hospitalization in high-risk populations. Preventive measures, including vaccines and monoclonal antibodies, are key to reducing its impact.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
